I cardiovascular prevention guideline of the Brazilian Society of Cardiology - executive summary.

Introduction

Brazil currently faces a major health challenge: the pandemic scenario of cardiovascular morbidity and mortality. According to Brazilian Health Ministry data, 326,000 deaths due to cardiovascular diseases (CVD) occurred in 2010, corresponding to approximately 1,000 deaths/day, 200,000 deaths due exclusively to ischemic heart and cerebrovascular diseases, reflecting a gloomy scenario far from the minimally acceptable control.

This current scenario can be attributed to many reasons, such as the insufficiency and inadequacy of public health policies for CVD prevention, leading to the well-known lack of infrastructure in primary health care, hindering the fight against preventable affections, mainly in the neediest areas.

In addition, it is worth mentioning the well-known sociocultural factors, such as the excessive consumption of high-caloric foods in association with physical inactivity, and, consequently, the development of obesity and diabetes, and excessive salt intake. Those factors contribute to the development of arterial hypertension, being decisive to the high prevalence of CVD and no opportunity to provide instructions on lifestyle changes.

The medical societies, in partnership with governments and universities, have endeavored to elaborate valuable documents containing strategic plans of CVD prevention and fight. However, simple and objective guidelines, which can be easily accessed and managed by health care personnel, are required to implement that which has been long discussed by specialists and scientists, although with modest results.

For the first time, guidelines and consensus documents, most of which already published in several other guidelines of specialties, have been gathered in a single document to provide the clinician with easy access to the recommendations for primary and secondary CVD prevention. For that, the Brazilian Society of Cardiology (SBC) has gathered specialized physicians with large experience in preventive actions to elaborate the present document.

Chapter 1 presents the cardiovascular risk stratification for atherosclerosis prevention and treatment. In this chapter, the authors discuss questions such as acute coronary event as the first manifestation of atherosclerotic disease in at least half of the individuals with that complication. Thus, the identification of predisposed asymptomatic individuals is crucial to the effective prevention with correct definition of therapeutic goals, especially the criteria to identify high-risk patients (Table 1). The authors discuss the so-called risk scores, through which the overall risk is calculated, enabling the clinician to quantify and qualify the patients' individual risk, for both women (Tables 2 and 3) and men (Tables 4 and 5). The combination of those different scores allow the clinician to better estimate the risk, stratifying it gradually: presence of significant atherosclerotic disease or its equivalents; calculation of risk score; aggravating factors (Chart 1) and risk stratification based on lifespan. The authors propose a simplified algorithm for cardiovascular risk stratification, which is exemplified in Figure 1. The recommendations listed as class I and level of evidence A are few, because the other recommendations still require more comprehensive studies with long-term follow-up (Table 6).

Table 1

Criteria to identify patients at high risk for coronary events (phase 1)

Atherosclerotic coronary artery, cerebrovascular or obstructive peripheral diseases with clinical manifestations (cardiovascular events) and still in the subclinical form, documented by use of diagnostic methodology;

Arterial revascularization procedures;

Type 1 and type 2 diabetes mellitus;

Chronic kidney disease.

Table 2

Scoring according to overall risk for women

Points	Age (years)	HDL-C	TC	SBP (untreated)	SBP (treated)	Smoking	Diabetes
-3				< 120
-2		60+
-1		50-59			< 120
0	30-34	45-49	< 160	120-129		No	No
1		35-44	160-199	130-139
2	35-39	< 35		140-149	120-129
3			200-239		130-139	Yes
4	40-44		240-279	150-159			Yes
5	45-49		280+	160+	140-149
6					150-159
7	50-54				160+
8	55-59
9	60-64
10	65-69
11	70-74
12	75+
Points							Total

HDL-C: high-density lipoprotein cholesterol; TC: total cholesterol; SBP: systolic blood pressure

Table 3

Overall cardiovascular risk in 10 years for women

Points	Risk (%)	Points	Risk (%)
≤-2	<1	13	10.0
-1	1.0	14	11.7
0	1.2	15	13.7
1	1.5	16	15.9
2	1.7	17	18.5
3	2.0	18	21.6
4	2.4	19	24.8
5	2.8	20	28.5
6	3.3	21 +	> 30
7	3.9
8	4.5
9	5.3
10	6.3
11	7.3
12	8.6

Table 4

Scoring according to overall risk for men

Points	Age (years)	HDL-C	TC	SBP (untreated)	SBP (treated)	Smoking	Diabetes
-2		60+		< 120
-1		50-59			< 120
0	30-34	45-49	< 160	120-129		No	No
1		35-44	160-199	130-139
2	35-39	< 35	200-239	140-159	120-129
3			240-279	160+	130-139		Yes
4			280+		140-159	Yes
5	40-44				160+
6	45-49
7
8	50-54
9
10	55-59
11	60-64
12	65-69
13
14	70-74
15	75+
Points							Total

HDL-C: high-density lipoprotein cholesterol; TC: total cholesterol; SBP: systolic blood pressure

Table 5

Overall cardiovascular risk in 10 years for men

Points	Risk (%)	Points	Risk (%)
≤-3 or less	<1	13	15.6
-2	1.1	14	18.4
-1	1.4	15	21.6
0	1.6	16	25.3
1	1.9	17	29.4
2	2.3	18+	> 30
3	2.8
4	3.3
5	3.9
6	4.7
7	5.6
8	6.7
9	7.9
10	9.4
11	11.2
12	13.2

Chart 1

Aggravating risk factors

• Family history of early coronary artery disease (male first-degree relative < 55 years-old or female first-degree relative < 65 years-old);
• Criteria of metabolic syndrome according to the International Diabetes Federation;
• Microalbuminuria (30-300 mg/min) or macroalbuminuria (>300 mg/min);
• Left ventricular hypertrophy;
• High-sensitivity C-reactive protein > 3 mg/L;
• Evidence of subclinical atherosclerotic disease:
	carotid stenosis/thickening > 1mm
	coronary calcium score > 100 or > 75th percentile for age or sex
	ankle-brachial test < 0.9

Figura 1

Algoritmo de estratificação do risco cardiovascular. ERG: estratificação do risco global; DAC: doença arterial coronariana; CV: cardiovascular; RTV: risco por tempo de vida

Table 6

Classification of recommendation and level of evidence for risk stratification in cardiovascular prevention

Recommendation	Class	Level of evidence
• Clinical manifestations of atherosclerotic disease or equivalents (type 1 or 2 diabetes mellitus and significant chronic kidney disease), even in primary prevention, have a risk > 20% in 10 years of new cardiovascular events or of the first cardiovascular event	I	A
• Patients classified as intermediate-risk with a family history of early cardiovascular disease will be reclassified as high-risk	Ila	B
• Men with a calculated risk for any of the events cited >5% and <20% and women with that calculated risk >5% and <10% are considered intermediate-risk	I	A
• Men with a calculated risk >20% and women with that calculated risk >10% are considered high-risk	I	A
• For individuals at intermediate risk, aggravating factors should be used, and when present (at least one) reclassify the individual as high-risk	Ila	B
• Use of risk according to lifespan for low- and intermediate-risk individuals aged >45 years	Ila	B

Chapter 2 approaches tobacco smoking, the major avoidable risk factor. It is known that 50% of the deaths of smokers, most of which caused by CVD, could be prevented with smoking cessation. In this chapter, the authors discuss preventive measures for tobacco use. Data from the Surveillance of Risk Factors and Protection Against Chronic Diseases via Telephone Inquiry (VIGITEL, in Portuguese), disclosed on April 2012, revealed advances in tobacco use control in Brazil, with 14.8% of smokers older than 18 years. They also approached the primordial prevention of tobacco use, enumerating factors that contribute to smoking initiation and proposing practical strategies for its combat. In addition, the authors discuss techniques to treat the psychological dependence of smokers with general and specific behavioral approaches. Furthermore, this chapter presents instruments to help to assess and understand the patient's profile by using universally accepted scales, such as Prochaska and Di Clemente's and Fagerström's. Finally, the authors approach, in a practical way, pharmacological treatment strategies of tobacco use, such as nicotine replacement with bupropion and varenicline, in addition to second-line drugs (nortriptyline), with their possible associations. Table 7 summarizes the classification of recommendation and level of evidence of those strategies.

Table 7

Classification of recommendation and level of evidence for the treatment of smoking in cardiovascular prevention

Recommendation		Class	Level of evidence
• Smoking is an independent risk factor for cardiovascular disease, therefore should be avoided		I	B
• Passive tobacco exposure increases the risk for cardiovascular diseases and should be avoided		I	B
• Pharmacological treatment of smoking		I	A
	Nicotine replacement	I	A
	Bupropion hydrochloride	I	A
	Varenicline tartrate	I	A

Chapter 3 discusses the real benefits of primary and secondary CVD prevention, with evident confirmation of diet, supplements and vitamins, aiming at helping the clinician to guide the community in choosing and consuming those products. In addition to supplements, omega-3 fatty acids, vitamins B, C, D and E, folates, alpha-linolenic acids and carotenoids were assessed (Tables 8).

Table 8

Summary of the recommendations for not using vitamin supplements to prevent cardiovascular disease (CVD) and recommendations for the consumption of products rich in omega-3 fatty acids

Indication	Class	Level of evidence
• There is no evidence that supplementation of vitamin A or beta-carotene is beneficial to the primary or secondary prevention of CVD	III	A
• Supplementations of vitamin B and folic acid are not effective to the primary or secondary prevention of CVD	III	A
• There is no evidence that supplementation of vitamin C is beneficial to CVD prevention, progression or mortality	II	A
• Supplementation of vitamin D is not recommended to CVD prevention in individuals with normal serum levels of that vitamin. Likewise, there is no evidence that supplementation in individuals with deficiency of that vitamin will prevent CVD.	III	C
• Marine omega-3 supplementation (2-4g/day) or even at higher doses should be recommended for severe hypertriglyceridemia (>500mg/dL), at risk for pancreatitis, refractory to nonpharmacological measures and drug treatment	I	A
• At least two fish-based meals per week, as part of a healthy diet, are recommended to reduce the cardiovascular risk. That is particularly recommended for high-risk individuals, such as those with previous myocardial infarction.	I	B
• Supplementation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) is not recommendedfor individuals at risk for cardiovascular disease undergoing evidence-based preventive treatment.	III	A
• The consumption of polyunsaturated omega-3 fatty acids of vegetable origin, as part of a healthy diet, should be recommended to reduce the cardiovascular risk, although the real benefit of that recommendation is arguable and the evidence is inconclusive.	IIb	B
• Alpha-linolenic acid (ALA) supplementation is not recommended for cardiovascular disease prevention.	III	B

Chapter 4 approaches obesity, overweight and nutrition transition, as well as the consequences for cardiovascular morbidity and mortality of their association with arterial hypertension, dyslipidemias, type 2 diabetes, osteoarthritides and cancer. Tables 9 and 10 list the classification of recommendation and levels of evidence for primary and secondary prevention.

Table 9

Summary of the recommendations for obesity and overweight in cardiovascular disease primary prevention

Indication	Class	Level of evidence
• Three healthy meals (breakfast, lunch and dinner) and two snacks per day	II	A
• Read food labels and choose those with the lowest amounts of trans fats	II	A
• Avoid sodas and industrialized juices, cakes, cookies and stuffed cookies, sweet desserts and other sweet treats	I	A
• Prefer having water between meals	II	A
• Exercise at least 30 minutes per day, everyday	I	A
• Individuals with a tendency to obesity or with a familial trend should exercise moderately 45-60 minutes per day; those previously obese, who lost weight, should exercise 60-90 minutes to prevent regaining weight	I	A
• Avoid the excessive consumption of alcoholic beverages	I	A

Table 10

Summary of the recommendations for obesity and overweight in cardiovascular disease secondary prevention

Indication	Class	Level of evidence
• Dietary caloric reduction of approximately 500 kcal/day	I	A
• Intensification of physical activity, such as walking, biking, swimming, aerobic exercises, 30-45 minutes, 3 to 5 times a week.	I	A
• Reduce sedentary activities, such as being seated for long periods watching TV, at computers or playing video games	I	B
• Encourage healthy eating for children and adolescents	I	B
• Sibutramine for weight loss in patients with cardiovascular disease	III	B
• Bariatric surgery for selected patients	I	B

Chapter 5 summarizes the recommendations for systemic arterial hypertension (SAH), emphasizing its importance for the development of several pathologies, such as coronary artery disease, heart failure, cerebrovascular disease and chronic kidney disease. Table 11 shows the routine initial assessment of hypertensive patients, and Table 12, its complementary assessment. Therapeutic decision should consider the patient's additional risk. Table 13 shows nonpharmacological measures, which are listed according to their recommendation class and level of evidence. Figure 2 shows the algorithm of pharmacological treatment based on the patients' hypertension stages. Monotherapy can be initiated with any drug class, but SAH control is only achieved in one-third of the cases with that strategy. Chart 2 shows the goals to be met according to patients' characteristics.

Table 11

Routine initial assessment of the hypertensive patient

Recommendation	Class	Level of evidence
• Urinalysis	I	C
• Serum potassium	I	C
• Serum creatinine	I	B
• Estimated glomerular filtration rate	I	B
• Fasting glycemia	I	C
• Total cholesterol, HDL-C, serum triglycerides	I	C
• Serum uric acid	I	C
• Conventional electrocardiogram	I	B

HDL-C: high-density lipoprotein cholesterol

Table 12

Complementary assessment of hypertensive patients

Recommendation		Class	Level of evidence
Chest X-ray		IIa	C
Echocardiography:	• stage 1 and 2 hypertensives without LVH on ECG	IIa	C
	• hypertensives with clinical suspicion of HF	I	C
Microalbuminuria:	• hypertensives and diabetic individuals	I	A
	• hypertensives with metabolic syndrome	I	C
	• hypertensives with 2 or + risk factors	I	C
Carotid ultrasound		IIa	B
Treadmill test when coronary artery disease is suspected		IIa	C
Glycosylated hemoglobin		IIa	B
Pulse wave velocity		IIb	C

LVH: left ventricular hypertrophy; ECG: electrocardiogram; HF: heart failure

Table 13

Nonpharmacological treatment of hypertensive patients

Recommendation		Class	Level of evidence
Diet	• DASH	I	A
	• Mediterranean	I	B
	• Vegetarian	IIa	B
Sodium: daily intake of 2g		I	A
Alcohol: do not exceed 30g of ethanol per day		I	B
Physical activity: 30 minutes/day/3 times a week (minimum)		I	A
Body weight control: BMI between 18.5 and 24.9 kg/m2		I	A
Psychosocial stress control		IIa	B
Multiprofessional team		I	B

DASH: Dietary Approaches to Stop Hypertension; BMI: body mass index

Figura 2

Algoritmo do tratamento da hipertensão arterial segundo a VI Diretrizes Brasileiras de Hipertensão Arterial

Chart 2

Blood pressure goals according to individual characteristics

Category	Consider
• Stage 1 and 2 hypertensives at low and moderate CV risk	< 140/90 mm Hg
• Hypertensives and borderline behavior with high and very high CV risk, or with 3 or + risk factors, DM, MS or TOL	130/80 mm Hg
• Hypertensives with kidney failure and proteinuria > 1.0 g/L	130/80 mm Hg

CV: cardiovacular; DM: diabetes mellitus; MS: metabolic syndrome; TOL: target-organ lesions.

Chapter 6 was aimed at discussing dyslipidemias, in an attempt to, after stratifying the individual risk, establish the therapeutic goals according to the overall risk level (low, intermediate or high). Specific goals are listed for high- and intermediate-risk patients. Patients at low cardiovascular risk should have their goals individualized at their clinician's discretion and according to lipid reference values. Table 14 presents strategies for lifestyle changes. Table 15 lists the pharmacological alternatives based on their recommendation class and level of evidence.

Table 14

Recommendations for the nonpharmacological treatment of dyslipidemia in cardiovascular prevention

Indication	Class	Level of evidence
• Control LDL-C	I	A
• Meet the recommended LDL-C level (primary goal)	I	A
• No goals proposed for HDL-C	I	A
• Reduce the intake of saturated fatty acids and trans fatty acids, and consume phytosterols (2-3 g/day) and soluble fibers	I	A
• Increase physical activity	I	A
• Reduce body weight and increase the ingestion of soy proteins; replace saturated fatty acids with mono- and polyunsaturated fatty acids	I	B
• Meet the recommended non-HDL-cholesterol level (secondary goal)	II	A
• Use proper therapy when triglyceride levels > 500 mg/dL to reduce the risk of pancreatitis, and use individualized therapy when triglyceride levels are between 150 and 499 mg/dL	II	A
• No goals proposed for apolipoproteins or lipoprotein(a)	II	A

Table 15

Recommendations for the pharmacological treatment of dyslipidemia

Indication	Class	Level of evidence
• Statins as the first drug option in primary and secondary prevention	I	A
• Use fibrates in monotherapy or in association with statins to prevent microvascular disease in patients with type 2 diabetes	I	A
• Association of ezetimibe or resins with statins when the LDL-C goal is not met	IIa	C
• Association of niacin with statins	III	A
• Use omega-3 fatty acids for cardiovascular disease prevention	III	A

Chapter 7 discusses diabetes, emphasizing its high prevalence in the adult population, up to 13.5% in some municipalities, which could represent a current population of 17 million individuals with diabetes. Those numbers are increasing due to factors such as population growth and aging, and increasing urbanization, sedentary lifestyle and obesity. This important chapter discusses essential measures for prevention, such as lifestyle changes (Table 16).

Table 16

Dietary and physical activity interventions in diabetes mellitus (DM) to prevent cardiovascular disease

Indication	Class	Level of evidence
• Moderate physical exercise for at least 150 minutes in association with moderate diet and energy restriction to prevent DM in individuals at risk	I	A
• Because of the effects of obesity on insulin resistance, weight loss is an important therapeutic goal for individuals at risk for DM	I	A
• Reduction in fat to less than 30% of the energy ingestion and reduced energy ingestion for overweight individuals	I	A

Chapter 8 provides a review on metabolic syndrome. There are several versions of the metabolic syndrome definition, and this guideline adopted the joint position paper of several international organizations on the topic. The authors discuss the epidemiological aspects of its prevalence, approaching different population groups, and aspects related to cardiovascular and metabolic risks, in addition to metabolic syndrome risk factors. Table 17 shows the recommendation class and level of evidence of interventions in metabolic syndrome.

Table 17

Interventions in metabolic syndrome (MS) to prevent cardiovascular disease

Indication	Class	Level of evidence
• A 5%-10% reduction in body weight in one year and long-term maintenance of weight lossare recommended	I	B
• A diet with low amounts of total, saturated and trans fats, in addition to adequate amounts of fibers, is recommended	I	B
• Physical activity for at least 30 minutes/day, preferably 45-60 minutes/day, 5 days a week, is recommended	I	B
• Individuals with impaired glucose tolerance on drug therapy can have a more expressive reduction in the incidence of MS or type 2 diabetes mellitus	I	B
• Individuals at metabolic risk and with abdominal circumference beyond the recommended limits should undergo a 5%-10% body weight reduction in one year	IIa	B
• Ingestion of less than 7% of total calories from saturated fat and of less than 200 mg/day of cholesterol in the diet is recommended	IIa	B

Chapter 9 discusses the role played by physical activity, physical exercise and sports in CVD prevention. Physically active individuals tend to be healthier and have better quality of life and longer life expectancy. Table 18 lists the recommended physical exercise levels. In addition, the risks of physical activity are approached, as well as the basic principles for exercise prescription and strategies to encourage referral, implementation and adherence.

Table 18

Recommended exercise levels for health promotion and maintenance

Exercise characteristics	Health benefits	Comments
• < 150 min/week of mild to moderate intensity	some	some exercise is certainly better than a sedentary lifestyle
• 150-300 min/week of moderate intensity	substantial	longer-duration and/or more intense exercise provides more benefits
• > 300 min/week of moderate to high intensity	additional	Current scientific data specifyan upper limit neither for benefits nor for damages to an additional apparently healthy individual

Chapter 10 discusses psychosocial factors in CVD prevention. Beginning with the definition of the concept, the chapter discusses the psychosocial conditions frequently associated with cardiovascular risk, such as low socioeconomic status, lack of social support, stress at work place and family life, depression, anxiety, hostility and type D personality. In addition, it assesses the recommendation class and level of evidence of approaching the psychosocial factors in primary prevention (Table 19) and for adherence (Table 20) by using cognitive-behavioral methods and indicating the 'ten strategic steps' to improve counseling for behavioral changes. Interventions on depression, anxiety and distress are also proposed as potential tools for adherence to preventive strategies (Chart 3), which can also be improved with the simple measures.

Table 19

Classification of recommendation and level of evidence in approaching psychosocial factors in primary prevention

Recommendation	Class	Level of evidence
• Behavioral changes with cognitive-behavioral strategy (motivational) I	I	A
• Integration of education and motivational strategies with a multiprofessional team whenever possible I	I	A
• Psychological or psychiatric consultation for more severe cases I	I	C
• Assessment of psychosocial risk factors IIa	IIa	B
• Pharmacological treatment and psychotherapy for patients with severe depression, anxiety and hostility, aimed at improving ^ the quality of life, despite lack of evidence	IIb	B

Table 20

Classification of recommendation and level of evidence of adherence to strategy in cardiovascular prevention, lifestyle and medication

Recommendation	Class	Level of evidence
• Assess and identify the causes of lack of adherence to define the proper orientation	I	A
• Use behavioral and motivational strategies for patients with persistent lack of adherence	IIa	A

Chart 3

Clinical strategy to improve adherence

Strategies to improve adherence
• Simplify dosage regimen	• Reduce the number of tablets and doses per day
• Reduce costs	• Lower cost drug
	• Generic drugs
	• Government subsidies and low-cost programs
• Proper communication	• Provide clear information about the benefits, possible adverse effects and duration of treatment
	• Assess without judging or criticizing the presence of poor adherence
	• Assess actively the presence of possible side effects (sexual dysfunction, cough, bleeding)
	• Avoid using technical terms and overloading the patient with a lot of information
• Behavioral strategies	• Incorporate the use of drugs to the patients' routine, suiting the dosage regimen to activities, meals and bedtime
	• Use tablet holders, electronic alarm devices, diaries, packages with calendars
	• Online support groups
	• Positive reinforcement (incentives, rewards)
	• Self-monitoring
	• Motivation counseling

Chapter 11 approaches dyslipidemia, obesity and SAH in childhood and adolescence. Brazilian population studies have shown a 10%-35% prevalence of dyslipidemia in children and adolescents. Table 21 shows the reference values for lipids and lipoproteins in those age groups.

Table 21

Reference values for lipids and lipoproteins in children and adolescents

Parameter	Acceptable	Borderline	High (p95)	Low (p5)
TC	< 170	170-199	> 200
LDL-C	< 110	110-129	> 130
n-HDL-C	123	123-143	> 144
TG (0-9a)	< 75	75-99	> 100
TG (10-19a)	< 90	90-129	> 130
HDL-C	> 45	35-45		< 35
Apo A1	> 120	110-120		< 110
Apo B	< 90	90-109	> 110

TC: total cholesterol; LDL-C: low-density-lipoprotein cholesterol; n-HDL-C: non-high-density-lipoprotein cholesterol; TG: triglycerides; HDL-C: high-density-lipoprotein cholesterol; Apo A1: apolipoprotein A1; Apo B: apolipoprotein B.

Table 22 shows the classification of SAH for children and adolescents. Changes in lifestyle are the initial therapeutic recommendation for primary SAH in children and adolescents. Pharmacological treatment is indicated for individuals with symptomatic hypertension, secondary hypertension, SAH target-organ lesion, types 1 and 2 diabetes mellitus, and persistent SAH despite the adoption of nonpharmacological measures, a situation in which such measures are an adjunct to the pharmacological treatment.

Table 22

Classification of arterial blood pressure in children and adolescents

Class	Percentile of systolic or diastolic blood pressure
Normal	< 90
Prehypertension (9)	90 to <95 or ≥ 120x80 mm Hg
Normal-high (10)
Stage 1 SAH	95 to 99 increased by 5 mm Hg
Stage 2 SAH	> 99 increased by 5 mm Hg

SAH: systemic arterial hypertension

The diagnosis of obesity or overweight in children is clinical, and should be established via history and physical exam, followed by comparison of anthropometric data with population parameters, by using curves of body mass index (BMI) for age. Prevention comprises adequate nutrition during pregnancy, breastfeeding encouragement, identification of familial risk factors, careful child's growth and development follow-up, habit changes, especially the adoption of a healthy diet and global increase in physical activity. It is important to involve the child's entire family, parents, teachers and health care professionals, in addition to count on a multidisciplinary team.

The systematic analysis of studies on the effectiveness of interventions to promote physical activity in the pediatric age group (more particularly adolescents) has shown better results when the actions associate school, family and community, and when the educational actions involve environmental and health policies.

Table 23 shows the recommendations and their levels of evidence to prevent CVD in children and adolescents.

Table 23

Classification of recommendation and level of evidence for the presence of cardiovascular diseases (CVD) in children and adolescents

Recommendation		Class	Level of evidence
Obesity screening
•	Obesity screening by use of BMI in children > 6 years, providing or indicating intensive behavioral interventions directed to achieving a healthy weight	I	B
•	Ask about early CAD family history to identify children at risk
•	In the presence of positive family history, assess all family members, especially the parents
•	In children aged > 2 years with BMI > 85th percentile:	I	C
	Reinforce preventive instructions (see below)
	Identify complications and RF: SBP, gallbladder disease symptoms, diabetes, sleep apnea, hypothyroidism, orthopedic disorders, lipid profile
•	In children aged > 2 years with BMI > 85th- 94th percentile,all measures above plus:t	I	C
	control of weight gain and fat ingestion, focusing on nutrition and developmen
	treatment of RF and complications
	multidisciplinary approach of moderate to high intensity
	measure aspartate aminotransferase (AST), alanine aminotransferase (ALT) and blood sugar in children > 10 years of age
•	In children aged > 2 years with BMI > 95th percentile, all measures above plus: Long-term objective: maintain BMI < 85	I	B
•	Consider more aggressive approaches if conservative strategies fail	I	A
•	Check urea and creatinine every 2 years
Nutrition - Milk/other beverages
Exclusive maternal breastfeeding for the first 6 months		I	B
From the 12th to the 24th month, transition to non-aromatic low-fat milk (2% or skim)		I	B
From 2 to 21 years of age, non-aromatic skim milk should be the major beverage		I	A
Avoid sugar beverages, encourage water ingestion		I	B
Dietary fat
Fat ingestion by infants should not be restricted without medical indication		I	C
From the 12th to the 24th month, transition to family meals with fat corresponding to 30% of the total caloric ingestion, 8%-10% of which of saturated fat		I	B
From 2 to 21 years of age, fat should correspond to 25%-30% of the total caloric ingestion, 8%-10% of which of saturated fat		I	A
Avoid trans fat		I	B
Cholesterol < 300 mg/dL		I	A
Others
From 2 to 21 years of age, encourage fiber ingestion, limit sodium ingestion and encourage healthy life habits: family meals, breakfast, limit fast snacks		I	B
Physical activity
Parents should create an environment that promotes physical activity and limit sedentary activities, and be role models		I	C
Limit sedentary activities, especially TV/video		I	B
Moderate to vigorous physical activity every day		I	A

BMI: body mass index; CAD: coronary artery disease; RF: risk factors; SBP: systolic blood pressure

Chapter 12 discusses topics related to legislation and prevention of CVD risk factors. The authors approach specific sanitary laws, discussing their effective role in health promotion and prevention, by creating healthy environments, in addition to emphasizing the importance of surveillance, prevention, health care, rehabilitation and health promotion

Chapter 13 discusses specific aspects of prevention of CVD associated with autoimmune diseases, influenza, chronic kidney disease, obstructive arterial disease, socioeconomic factors, obstructive sleep apnea, erectile dysfunction and periodontitis (Table 24).

Table 24

Recommendation for approaching special conditions in cardiovascular disease prevention

Recommendation	class	level of evidence
• In the context of preventing cardiovascular events, the benefit of using more strict therapeutic targets, especially due to the presence of autoimmune diseases, is uncertain.	IIb	C
• Annual influenza vaccination for patients with established coronary artery or cerebrovascular disease, regardless of age	I	B
• Annual influenza vaccination for patients at high risk for coronary events, but with no cardiovascular disease, regardless of age.	IIa	C
• Patients with chronic kidney disease should be considered at very high risk for cardiovascular risk factors, requiring the assessment of glomerular filtration rate reduction and presence of co-morbidities.	I	C
• Patients with obstructive arterial disease should be considered at very high risk, similarly to that of manifest coronary artery disease, for approaching cardiovascular risk factors.	I	C
• Socioeconomic indicators should be investigated in clinical assessment and considered when approaching a patient, to improve quality of life and the prognosis of cardiovascular diseases.	IIa	B
• All patients with obstructive sleep apnea should be considered as potential candidates to primary prevention, undergo cardiovascular risk stratification and be treated according to estimated risk.	IIa	A
• All men with erectile dysfunction should be considered as potential candidates to primary prevention, undergo cardiovascular risk stratification and be treated according to estimated risk.	IIa	B
• Patients with periodontitis should be considered for cardiovascular risk stratification and intensive local treatment.	IIa	B

We provide the medical class with a guideline that gathers, in one single publication, compiled and updated essential prevention topics to be used as a reference in CVD prevention.